Neoadjuvant therapy in non-small cell lung cancer

Christopher Grant; Garo Hagopian; Misako Nagasaka

doi:10.1016/j.critrevonc.2023.104080

Neoadjuvant therapy in non-small cell lung cancer

Crit Rev Oncol Hematol. 2023 Oct:190:104080. doi: 10.1016/j.critrevonc.2023.104080. Epub 2023 Aug 1.

Authors

Christopher Grant¹, Garo Hagopian¹, Misako Nagasaka²

Affiliations

¹ Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
² Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Hematology and Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; Division of Neurology, Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address: nagasakm@hs.uci.edu.

PMID: 37532102
DOI: 10.1016/j.critrevonc.2023.104080

Abstract

Non-small cell lung cancer (NSCLC) stages I-III were previously predominantly treated with surgery and chemotherapy. With the advent of Checkmate-816, neoadjuvant nivolumab and chemotherapy was FDA approved for the treatment of resectable NSCLC. There are several ongoing trials evaluating other neoadjuvant combinations of chemotherapy and immunotherapy as well as targeted therapies towards driver mutations. Here, we review previous clinical trials and discuss current ongoing trials' potential benefits and challenges.

Keywords: AEGEAN; CheckMate 816; Neoadjuvant targeted therapy; Perioperative chemotherapy; Perioperative immunotherapy.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / surgery
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / surgery
Neoadjuvant Therapy
Nivolumab / therapeutic use

Substances

Nivolumab